Prognostic ability of the neoadjuvant rectal (NAR) score in long‐course concurrent chemoradiotherapy for patients with locally advanced rectal cancer: a retrospective cohort study

Abstract

Background: The aims of this study were to evaluate the prognostic ability of the neoadjuvant rectal (NAR) score and to develop and validate a nomogram based on the NAR for patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (nCRT).

Methods: In total, 307 patients, including 230 patients from the primary cohort and 77 from the external cohort, were enrolled across the two centers. The associations of the NAR score with the tumor response, tumor control, and clinicopathological parameters were analyzed. Survival analysis was performed in the primary and external cohorts using Kaplan‒Meier curves. Univariate and multivariate analyses were performed to evaluate the prognostic factors. The NAR‐based nomogram was developed in the primary cohort and validated in the external cohort using the concordance index (C‐index), calibration plots, and decision curve analyses (DCAs).

Results: Kaplan‒Meier survival analysis revealed that the disease‐free survival (DFS) and overall survival (OS) of the NAR > 16 group were significantly lower than those of the NAR ≤ 16 group (p < 0.001). Multivariate Cox regression analysis identified the NAR score as an independent prognostic factor for both DFS (hazard ratio [HR] = 2.484, 95% confidence interval [CI]: 1.159−5.323, p = 0.019) and OS (HR = 4.633, 95% CI: 1.076−19.941, p = 0.04). Calibration plots and DCAs showed that NAR‐based nomograms for DFS and OS were consistent and useful in clinical practice. Moreover, the C‐indexes of the NAR‐based nomograms were better than those of the other variables in both the primary and external cohorts.

Conclusion: Our study validates the prognostic role of the NAR score for DFS and OS. The NAR‐based nomogram for OS could accurately predict the outcome of LARC patients by stratifying the risk score accordingly.

Keywords

NAR score / rectal cancer / prognosis / nomogram

References

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394- 424.

[2] Qu R, Ma Y, Tao L, et al. Features of colorectal cancer in China stratified by anatomic sites: a hospital-based study conducted in university-affiliated hospitals from 2014 to 2018. Chin J Cancer Res. 2021; 33 (4): 500- 511.

[3] Qu R, Ma Y, Zhang Z, Fu W. Increasing burden of colorectal cancer in China. Lancet Gastroenterol Hepatol. 2022; 7 (8): 700.

[4] Chang H, Yu X, Chen K, et al. Prognostic value of the cycle number of perioperative chemotherapy in locoregionally advanced rectal cancer: a propensity score matching analysis. J Cancer. 2018; 9 (23): 4346- 4354.

[5] Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351 (17): 1731- 1740.

[6] Omejc M, Potisek M. Prognostic significance of tumor regression in locally advanced rectal cancer after preoperative radiochemotherapy. Radiol Oncol. 2018; 52 (1): 30- 35.

[7] Lee SY, Jo JS, Kim HJ, Kim CH, Kim YJ, Kim HR. Prognostic factors for low rectal cancer patients undergoing intersphincteric resection after neoadjuvant chemoradiation. J Surg Oncol. 2015; 111 (8): 1054- 1058.

[8] George, Jr. TJ, Allegra CJ, Yothers G. Neoadjuvant rectal (NAR) score: a new surrogate endpoint in rectal cancer clinical trials. Curr Colorectal Cancer Rep. 2015; 11 (5): 275- 280.

[9] Ho SS, Hon SS, Hung E, et al. Prognostic implication of the neoadjuvant rectal score and other biomarkers of clinical outcome in Hong Kong Chinese patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy. Hong Kong Med J. 2022; 28 (3): 230- 238.

[10] Huang WS, Kuan FC, Lin MH, Chen MF, Chen WC. Prognostic significance of neoadjuvant rectal scores in preoperative short- course radiotherapy and long-course concurrent chemoradiotherapy for patients with locally advanced rectal cancer. Ann Surg Oncol. 2020; 27 (11): 4309- 4318.

[11] Lim YJ, Song C, Jeon SH, Kim K, Chie EK. Risk stratification using neoadjuvant rectal score in the era of neoadjuvant chemoradiotherapy: validation with long-term outcome data. Dis Colon Rectum. 2021; 64 (1): 60- 70.

[12] Roselló S, Frasson M, García-Granero E, et al. Integrating downstaging in the risk assessment of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: validation of Valentini's Nomograms and the neoadjuvant rectal score. Clin Colorectal Cancer. 2018; 17 (2): 104- 112.

[13] Fokas E, Fietkau R, Hartmann A, et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. Ann Oncol. 2018; 29 (7): 1521- 1527.

[14] Deng Y, Cai Y, Zhang J, et al. Validation of neoadjuvant rectal cancer(NAR) score as a surrogate endpoint for disease free survival in Chinese FOWARC study. J Clin Oncol. 2019; 37: e15162.

[15] Yothers G, George TJ, Allegra CJ, et al. Predictive validity of neoadjuvant rectal (NAR) score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial. J Clin Oncol. 2016; 34 (15): 3533.

[16] Sert F, Ozturk M, Yalman D, Ozkok S. Does neoadjuvant rectal score predict treatment outcomes better than the all grading systems used in neoadjuvantly treated rectal cancer? Asian J Surg. 2022; S1015‐9584 (22): 01385- 9.

[17] Baek JH, Baek DW, Kang BW, et al. Prognostic impact of the neoadjuvant rectal score as compared with the tumor regression grade and yield pathologic TNM stage in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy. In Vivo. 2020; 34 (4): 1993- 1999.

[18] Weiser MR, Chou JF, Keshinro A, et al. Development and assessment of a clinical calculator for estimating the likelihood of recurrence and survival among patients with locally advanced rectal cancer treated with chemotherapy, radiotherapy, and surgery. JAMA Netw Open. 2021; 4 (11): e2133457.

[19] Lu S, Liu Z, Wang B, et al. High CFP score indicates poor prognosis and chemoradiotherapy response in LARC patients. Cancer Cell Int. 2021; 21 (1): 205.

[20] Lu S, Liu Z, Zhou X, et al. Preoperative Fibrinogen-Albumin ratio index (FARI) is a reliable prognosis and chemoradiotherapy sensitivity predictor in locally advanced rectal cancer patients undergoing radical surgery following neoadjuvant chemoradiotherapy. Cancer Manag Res. 2020; 12: 8555- 8558.

[21] Valentini V, van Stiphout RGPM, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011; 29 (23): 3163- 3172.

[22] Gelsomino F, Bertolini F, Luppi G, et al. A dose-finding and biomarker evaluation phase ib study of everolimus in association with 5-fluorouracil and pelvic radiotherapy as neoadjuvant treatment of locally advanced rectal cancer (E-LARC Study). Clin Colorectal Cancer. 2017; 16 (4): 410- 415.

[23] Rahma OE, Yothers G, Hong TS, et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol. 2021; 7 (8): 1225- 1230.

[24] Mehta R, Frakes J, Kim J, et al. Phase I study of lenvatinib and capecitabine with external radiation therapy in locally advanced rectal adenocarcinoma. Oncologist. 2022; 27 (8): 621- e617.

[25] Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J. 2009; 15 (5): 401- 405.

[26] Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol. 2010; 7 (6): 309- 317.

[27] Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008; 113 (1): 57- 64.

[28] Weiser MR, Gönen M, Chou JF, Kattan MW, Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol. 2011; 29 (36): 4796- 4802.

[29] Trakarnsanga A, Gönen M, Shia J, et al. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J Natl Cancer Inst. 2014; 106 (10): dju248.

[30] van der Valk MJM, Vuijk FA, Putter H, van de Velde CJH, Beets GL, Hilling DE. Disqualification of neoadjuvant rectal score based on data of 6596 patients from the Netherlands cancer registry. Clin Colorectal Cancer. 2019; 18 (2): e231- e236.

RIGHTS & PERMISSIONS

2023 Higher Education Press